MedKoo Cat#: 571191 | Name: A 78773

Description:

WARNING: This product is for research use only, not for human or veterinary use.

A 78773 is a potent, selective, direct, and reversible 5-lipoxygenase inhibitor. It has activity in a variety of purified cells and in more complex biological systems such as whole blood, lung fragments, and tracheal tissues. A 78773 acts against inflammation and allergy, edema, inflammatory cell influx, and bronchospasm. It may treat asthma and inflammatory bowel disease.

Chemical Structure

A 78773
A 78773
CAS#141579-67-1

Theoretical Analysis

MedKoo Cat#: 571191

Name: A 78773

CAS#: 141579-67-1

Chemical Formula: C15H13FN2O4

Exact Mass: 304.0859

Molecular Weight: 304.28

Elemental Analysis: C, 59.21; H, 4.31; F, 6.24; N, 9.21; O, 21.03

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
A 78773; A-78773; A78773
IUPAC/Chemical Name
Urea, N-(3-(5-(4-fluorophenoxy)-2-furanyl)-1-methyl-2-propynyl)-N-hydroxy-
InChi Key
OLZHFFKRBCZHHT-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H13FN2O4/c1-10(18(20)15(17)19)2-5-12-8-9-14(21-12)22-13-6-3-11(16)4-7-13/h3-4,6-10,20H,1H3,(H2,17,19)
SMILES Code
O=C(N)N(C(C)C#CC1=CC=C(OC2=CC=C(F)C=C2)O1)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 304.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bell RL, Lanni C, Malo PE, Brooks DW, Stewart AO, Hansen R, Rubin P, Carter GW. Preclinical and clinical activity of zileuton and A-78773. Ann N Y Acad Sci. 1993 Nov 30;696:205-15. PubMed PMID: 8109828. 2: Rao TS, Currie JL, Shaffer AF, Isakson PC. Evaluation of 5-lipoxygenase inhibitors, zileuton, A-78773 and ICI-D-2138 in an ionophore (A-23187)-induced pleural inflammation model in the rat. Life Sci. 1993;53(9):PL147-52. PubMed PMID: 8394967. 3: Bell RL, Brooks DW, Young PR, Lanni C, Stewart AO, Bouska J, Malo PE, Carter GW. A-78773: a selective, potent 5-lipoxygenase inhibitor. J Lipid Mediat. 1993 Mar-Apr;6(1-3):259-64. PubMed PMID: 8395248. 4: Carter GW, Bell RL, Marsh K, Lanni C, Awni WM, Bouska J, Stewart AO, Hansen R, Dubé L, Brooks DW. Stereoselective metabolism of the 5-lipoxygenase inhibitor A-78773. Ann N Y Acad Sci. 1994 Nov 15;744:262-73. PubMed PMID: 7825849. 5: Smith WG, Shaffer AF, Currie JL, Thompson JM, Kim S, Rao T, Isakson PC. Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays. J Pharmacol Exp Ther. 1995 Dec;275(3):1332-8. PubMed PMID: 8531100. 6: Nair DG, Funk CD. A cell-based assay for screening lipoxygenase inhibitors. Prostaglandins Other Lipid Mediat. 2009 Dec;90(3-4):98-104. doi: 10.1016/j.prostaglandins.2009.09.006. Epub 2009 Oct 3. PubMed PMID: 19804839. 7: Li R, Mayer PT, Trivedi JS, Fort JJ. Polymorphism and crystallization behavior of Abbott-79175, a second-generation 5-lipoxygenase inhibitor. J Pharm Sci. 1996 Jul;85(7):773-80. PubMed PMID: 8819005. 8: Negro JM, Miralles JC, Ortiz JL, Funes E, García A. Biosynthesis inhibitors for leukotrienes in bronchial asthma. Allergol Immunopathol (Madr). 1997 Jul-Aug;25(4):209-16. Review. PubMed PMID: 9269512. 9: Bell RL, Bouska JB, Malo PE, Lanni C, Harris RR, Otis ER, Stewart AO, Brooks DW, Carter GW. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. J Pharmacol Exp Ther. 1995 Feb;272(2):724-31. PubMed PMID: 7853186. 10: Anderson GD, Keys KL, De Ciechi PA, Masferrer JL. Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. Inflamm Res. 2009 Feb;58(2):109-17. doi: 10.1007/s00011-009-8149-3. PubMed PMID: 19184362. 11: McLoughlin M, Kearney AS, Palepu NR. Aqueous stability of SB 210661: kinetics and primary degradation mechanisms of an N-hydroxyurea-containing 5-lipoxygenase inhibitor. J Pharm Pharmacol. 1998 Feb;50(2):127-32. PubMed PMID: 9530978. 12: Harris RR, Wilcox D, Bell RL, Carter GW. The role of tissue mast cells in polyacrylamide gel-induced inflammation in mice. Inflamm Res. 1998 Mar;47(3):104-8. PubMed PMID: 9562335. 13: Rioux N, Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis. 1998 Aug;19(8):1393-400. PubMed PMID: 9744535. 14: Hulkower KI, Pollock JS, Walsh RE, Huang R, Otis ER, Brooks CD, Bell RL. Leukotrienes do not regulate nitric oxide production in RAW 264.7 macrophages. Prostaglandins Leukot Essent Fatty Acids. 1996 Sep;55(3):145-9. PubMed PMID: 8931110. 15: Howarth PH, Harrison K, Lau L. The influence of 5-lipoxygenase inhibition in allergic rhinitis. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):423-4. PubMed PMID: 7613199.